Makiko Hatori Email & Phone Number

Developing clinical diagnostic assays utilizing single-cell whole genome sequencing to enhance the accuracy of genetic profiling.Implementing Illumina and Nanopore sequencing to streamline data collection processes, reducing turnaround times and increasing throughput.

【Development of NGS based early stage cancer diagnostic kits for nanopore sequencer】• Point lead for designing and evaluating sequencing adapters. Successfully increased the NGS library preparation efficiency by 20% compared to original adapter design. • Proposed novel ideas to improve assay performance that involved increasing assay sensitivity. As a result assay efficiency was increased by 8% compared to existing assay. The ideas also lead to a significant reduction in hands-on time for the product, from 5 days to 4 days. These assay improvements were also applicable to other products in the company line-up and had a portfolio level impact.• Organized meetingWorked closely with manufacturing and late development teams to transfer project to next phase

San Francisco Bay Area

【Established novel droplet generation methods for single cell assays which does not require specialized skills】• First author for 2 papers and in charge of experiment planning, experiment execution, and manuscript preparation.• Significantly increases the accessibility of droplet assays for laboratories that do not specialize in microfluidics. By using vortexing as a means of droplet formation, the method eliminates complex, expensive instrumentation and microfluidics consumables. • This scalable droplet generation method enables the preparation of up to 40 millions samples with reduced preparation time from 12 hours to 30 seconds.• Successfully developed 3 applications with this method, involving ddPCR, single cell RNA sequencing and DNA sequencing • Filed for 3 patents【Development of point of care test kit for COVID】• Demonstrated a new method to detect COVID virus by employing LAMP based amplification. Increased sensitivity by 20% and reduced the time to get results by 50%.• Partnered with a start-up company and evaluated assay to develop test kits using this method.

United States

【Revealed the mechanism of signaling protein dispersion during tumorigenesis】• To understand signaling pathway, tagged endogenous signaling protein using Crispr-Cas9 • Designed and cloned template and gRNA vector for tag and indel introduction• Fluorescent live imaging of tagged proteins reveal the mechanism of signaling protein dispersion during tumorigenesis

Tokyo, Japan

【Conducted clinical trial】• Worked as clinical research associate• Design the protocol for atrial fibrillation for phase II and asthma for phase I

Japan

【Discovered a new protein that has crucial role for membrane trafficking events】• To understand tumor genesis and virus infection, I studied molecular mechanisms for clathrin-mediated endocytosis using budding yeast. • Generated over 100 of mutant strains (knockout/knockin/point mutation/indels).• Discovered the a new protein, Srv2p, required for this pathway and demonstrated in vivo role of this protein in the regulation of the actin cytoskeleton.